Presentation1 (8).pptx

SCHOOL OF NURSING,DEPARTMENT OF CARDIOVASCULAR NURSING
SEMINAR PRESENTATION ON HTN
BY:JIREGNA ETICHA GSRC /4247/14
: HABTAMU MULU GSRC/4236/14
INSTRUCTOR: (TAKALEGN, MSC IN CVNGP)
April 27/2022
Out line
Objective
 Introduction
Hypertension
Systolic Blood
Pressure (SBP)
Diastolic Blood
Pressure (DBP)
> 140 mmHg > 90 mmHg
Determinant's BP
 BP=CO X SVR=HR X EDV - ESV X SVR
 CO=HR X SV
 CO=is defined as amount of blood pumped out of each ventricle per minute.
 HR=The number of times your heart beats per minute (BPM)
 SV=is the volume of blood pumped from one ventricle of the heart with each beat.
 SV = EDV – ESV
 SRV=Vascular function and structure.
INTRODUCTION
 Arterial hypertension, simply started is high blood pressure. It is
defined as a persistent evaluation of the systolic blood pressure at
a level of 140 mm Hg or higher and diastolic blood pressure at a
level of 90 mm Hg or higher.
CLASSIFICATION OF HTN
Classification Systolic blood pressure Diastolic pressure
Normal ≤120 ≤ 80
Pre HTN 120-139 80-89
High BP Stage 1 140-159 90-99
High BP Stage 2 Higher than 160 Higher than 100
Risk factors
 Family history
 Age
 Gender
 Ethnicity
 Diabetes
 Stress
 Obesity
 Nutrients
 Substance abuse
Clinical manifestation
 Silent killer
 Headache
 Nausea and vomiting
 Fatigue and confusion
 Chest pain
 Dizziness
 Epistaxis
 Angina
 Dyspnea
 Severe head ache
 Blurred vision
 Irregular heart beat
 papilledema
Complications
 CAD
 LVH
 Heart attack / stroke
 HF
 Retinal damage
 Atherosclerosis
 Peripheral vascular disease
Types
1.Primary HTN / essential 95%
 Is the most common form of hypertension.
 The cause of primary hypertension is unknown.
2.Secondary HTN 5%
3.Systolic Isolated Hypertension
 It’s a high value of systolic pressure, and a normal value of diastolic pressure
4. Hypertensive crisis
Hypertensive Urgencies
 Hypertensive urgency is acute severe elevation in blood pressure (>180/120 mmHg)
without evidence of end organ damage
 Usually due to under-controlled HTN.
Hypertensive Emergencies
 A severe elevation in blood pressure (usually >180/120 mmHg) complicated by
impending or progressive target organ dysfunction involving neurological, cardiac or
renal systems”
 Require lowering of BP within 1 hour to decrease morbidity
 Not determined by a BP level, but rather the imminent compromise of vital organ
function
Risk Factors for Primary Hypertension
 Age (> 55 for men; > 65 for women)
 Alcohol
 Cigarette smoking
 Diabetes mellitus
 Elevated serum lipids
 Excess dietary sodium
 Gender Risk Factors for Primary Hypertension
 Family history
 Obesity (BMI > 30)
 Ethnicity (African Americans)
 Sedentary lifestyle
 Socioeconomic status
 Stress
2. Secondary HTN
 Some people have high blood pressure caused by an underling condition.
 This type of high blood pressure called secondary hypertension. Various
condition and medications can lead to secondary hypertension.
 Renal artery stenosis
 Oral contraceptive pills
 Illegal drugs
Conti….
 Sleep apnea
 Drug-induced or drug-related
 Chronic kidney disease
 Primary aldosteronism
 Reno vascular disease
 Chronic steroid therapy and Cushing syndrome
 Phaeochromocytoma
 Acromegaly
 Thyroid or parathyroid disease
 Coarctation of the aorta
Other types of HTN
1. White coat hypertension
 White coat syndrome have normal reading at home and only have high readings
when their BP is taken by a doctor.
2.Isolated systolic hypertension
 It’s not uncommon to have either a systolic number that’s elevate while the
diastolic number remains normal.
 It’s less common for patients to have elevated diastolic number.
 This condition known as isolated systolic hypertension
3.Persistent Hypertension
 Characterized by a diastolic blood pressure above 110 to 120 mm Hg.
 It results when hypertension is unresponsive to treatment and become a truly
severe emergency condition as the pressure continues to rise unchecked
Benign hypertension
 is a term used to describe uncomplicated hypertension,
usually of long duration and mild to moderate severity.
 Benign hypertension may be primary or secondary.
Malignant hypertension
 is a syndrome of markedly elevated BP (diastolic BP over 140
mm Hg) associated with papilledema.
 Accelerated hypertension is a syndrome of markedly elevated
BP with retinal hemorrhage and exudates.
 Accelerated hypertension presumably develops into malignant
hypertension if not well managed.
Borderline or labile hypertension
 is defined as intermittent elevation of blood pressure
interspersed with normal readings.
 Clients with borderline hypertension still carry an increased
risk of developing cardiovascular disease.
Resistant hypertension
 Resistant hypertension is defined as blood pressure that remains
above goal in spite of the concurrent use of 3 antihypertensive
agents of different classes. Ideally, one of the 3 agents should be a
diuretic and all agents should be prescribed at optimal dose
amounts
Diagnostic Evaluation
 History collection and physical examination
 Medical history of diabetes mellitus
 Complete blood count
 Chest x-ray
 ECG
 Ophthalmoscopy/Funduscopy
laboratory Tests
 Renal
 Microscopic urinalysis, proteinuria, BUN and/or creatinine
 Endocrine,
 Serum sodium, potassium, calcium, TSH
 Metabolic
 Fasting blood glucose, HDL, LDL, and total cholesterol, triglycerides
Management
1.Non pharmacological management
2. Pharmacological management
1.Non pharmacological management
 Lifestyle modifications
 Sodium restriction
 Nutritional therapy
 Physical activity
 Alcohol restriction
 Relaxation technique
 Weight reduction
 DASH Diet : Dietary Approaches to Stop Hypertension
2.Pharmacological management
1.ACEI
 Angiotensin is a hormone in the body that causes blood vessels to narrow.
 The angiotensin converting enzyme inhibitors decreases the production of angiotensin
and in turn that helps lower blood pressure.
 Inhibit ACE and formation of angiotensin II and block its effects
 Drugs of choice in co-existent diabetes mellitus, Heart failure
 Captopril (25-150 mg/day)
 Ramipril (1.25-20 mg/day)
 Lisinopril
2. Alpha blockers
 These medicines reduces nerve impulses to blood vessels, reducing the
effects of natural chemicals that narrow blood vessels.
 Block α-1 receptors and cause vasodilation
 Reduce peripheral resistance and venous return
 Exert beneficial effects on lipids and insulin sensitivity
 Drugs of choice in patients with co-existing BPH
 Prazocin (2-30 mg/day)
 Terazocin (1-20 mg/day)
3. Alpha- beta blockers
 In addition to reducing nerve impulses to blood vessels, alpha beta blockers
slow the heartbeat to reduce the amount of blood that must be pumped through
the vessels.
 Help relax your blood vessels, which lowers your blood pressure.
 Labetalol (2-30 mg/day)
 Carvedilol (12.5-20 mg/day)
4. Angiotensin II receptor blockers
 These medications help relax blood vessels by blocking the action, not
the formation of a natural chemical that narrows blood vessels.
 Block the angiotensin II receptor and inhibit effects of
angiotensin II
 Drugs of choice in patients with co-existing diabetes mellitus
 Valsartan
 losartan
5.Beta blockers
 These medications reduce the workload on heart and open blood vessels, causing
heart to beat slower and with less force.
 Example: Atenolol, Metoprolol, nebivolol,
 Block β1 receptors on the heart
 Block β2 receptors on kidney and inhibit release of renin
 Decrease rate and force of contraction and thus reduce cardiac output
 Drugs of choice in patients with co-existent coronary heart disease
6. Calcium channel blockers
 These medicines will block the movement of extra cellular calcium into the cells and causing
vasodilation and decreased heart rate.
 These medications relax the muscles of blood vessels. Some slow the heart rate.
 Calcium channel blockers relax blood vessels by stopping calcium from entering cells
 Cause vasodilation and reduce peripheral resistance
 Drugs of choice in elderly hypertensive and those with co-existing asthma
 Neutral effect on glucose and lipid levels
Example: Amlodipine
7. Diuretics
 Example: Hydrochlorothiazide :-Act by decreasing blood volume and cardiac
output •
 Decrease peripheral resistance during chronic therapy
 Drugs of choice in elderly hypertensive
 Diuretics help the kidneys get rid of sodium and water from body. This decreases the
volume of blood in the body and lowers blood pressure.
 Diuretics are also called water pills. They help your kidneys remove some salt (sodium)
from your body. As a result, your blood vessels don't have to hold as much fluid and your
blood pressure goes down
 E.g. chlorothiazide, furosemide
 Furosemide (40-240mg/day)
 Spironolactone (25-100 mg/day
8.Vasodilators
 These medications acting directly on the muscles in the wall of arteries and
preventing the muscles from tightening and arteries from narrowing. These
medications work directly on the muscles in the walls of arteries.
 signal the muscles in the walls of blood vessels to relax
E.g. Nitroglycerin, Sodium nitro prusside
 Minoxidil (5-100 mg/day)
 Hydralazine (50-300 mg/day)
9.Centrally acting drugs
 signal your brain and nervous system to relax your blood vessels
 Step to Management
Lifestyle modifications
weight loss, diet, exercise, stop smoking, limit alcohol
Medication
Diuretics or Beta-Blocker
Add second drug or substitute another drug
Add third drug and/or substitute second drug
Continue adding agents from other classes
Referral to hypertensive specialist
Step 1
Step 2
Step 3
Step 4
Step 5
Algorithm of HTN Management
THANK YOU!!!!!
1 de 36

Recomendados

Hypertension por
HypertensionHypertension
HypertensionNandkishor Jha
990 visualizações56 slides
Essential hypertension management and treatment por
Essential hypertension management  and treatmentEssential hypertension management  and treatment
Essential hypertension management and treatmentFabio Grubba
3.1K visualizações31 slides
Hypertension por
HypertensionHypertension
HypertensionSarah Shah
1K visualizações64 slides
Hypertension por
HypertensionHypertension
HypertensionTosca Torres
6.2K visualizações18 slides
hypertension.pptx por
hypertension.pptxhypertension.pptx
hypertension.pptxNgulakehBlaise1
251 visualizações43 slides
Antihypertensive drugs and hypertension management por
Antihypertensive drugs and hypertension managementAntihypertensive drugs and hypertension management
Antihypertensive drugs and hypertension managementAnas Indabawa
1.9K visualizações25 slides

Mais conteúdo relacionado

Similar a Presentation1 (8).pptx

Hypertension Guidelines By Rodgers Chibale por
Hypertension Guidelines By Rodgers ChibaleHypertension Guidelines By Rodgers Chibale
Hypertension Guidelines By Rodgers ChibaleRodgersChibale
53 visualizações34 slides
Lec 7 hypertension for mohs por
Lec 7  hypertension for mohsLec 7  hypertension for mohs
Lec 7 hypertension for mohsEhealthMoHS
188 visualizações59 slides
Htn05 por
Htn05Htn05
Htn05pharmdude
15.6K visualizações85 slides
Understanding hypertension por
Understanding hypertensionUnderstanding hypertension
Understanding hypertensionReynel Dan
1.5K visualizações50 slides
Hypertension por
HypertensionHypertension
Hypertensiondhavalshah4424
8.9K visualizações36 slides
Hypertension cme -dr.saranya por
Hypertension cme -dr.saranya Hypertension cme -dr.saranya
Hypertension cme -dr.saranya Dr.Sabari Nathan
2K visualizações43 slides

Similar a Presentation1 (8).pptx(20)

Hypertension Guidelines By Rodgers Chibale por RodgersChibale
Hypertension Guidelines By Rodgers ChibaleHypertension Guidelines By Rodgers Chibale
Hypertension Guidelines By Rodgers Chibale
RodgersChibale53 visualizações
Lec 7 hypertension for mohs por EhealthMoHS
Lec 7  hypertension for mohsLec 7  hypertension for mohs
Lec 7 hypertension for mohs
EhealthMoHS188 visualizações
Htn05 por pharmdude
Htn05Htn05
Htn05
pharmdude15.6K visualizações
Understanding hypertension por Reynel Dan
Understanding hypertensionUnderstanding hypertension
Understanding hypertension
Reynel Dan1.5K visualizações
Hypertension por dhavalshah4424
HypertensionHypertension
Hypertension
dhavalshah44248.9K visualizações
Hypertension cme -dr.saranya por Dr.Sabari Nathan
Hypertension cme -dr.saranya Hypertension cme -dr.saranya
Hypertension cme -dr.saranya
Dr.Sabari Nathan2K visualizações
NurseReview.Org - Antihypertensives Updates (pharmacology review notes) por jben501
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
jben5013.6K visualizações
Antihypertensives por raj kumar
AntihypertensivesAntihypertensives
Antihypertensives
raj kumar84.1K visualizações
Hypertension por lavanyaravi13
HypertensionHypertension
Hypertension
lavanyaravi1360 visualizações
Hypertension por AmangKipa
HypertensionHypertension
Hypertension
AmangKipa521 visualizações
Hypertension por Aizaz919930
HypertensionHypertension
Hypertension
Aizaz91993048 visualizações
hypertension, CCF por ligi xavier
hypertension, CCFhypertension, CCF
hypertension, CCF
ligi xavier5.7K visualizações
Htn urgency and emg por Sudhir Dev
Htn urgency and emgHtn urgency and emg
Htn urgency and emg
Sudhir Dev1.7K visualizações
Pharmacotherapy for hypertension por Koppala RVS Chaitanya
Pharmacotherapy for hypertension Pharmacotherapy for hypertension
Pharmacotherapy for hypertension
Koppala RVS Chaitanya11.4K visualizações
hypertension final.ppt por chiapas52
hypertension final.ppthypertension final.ppt
hypertension final.ppt
chiapas5250 visualizações
hypertension final.ppt por RDScreenTV
hypertension final.ppthypertension final.ppt
hypertension final.ppt
RDScreenTV29 visualizações
hypertension final.ppt por derek462361
hypertension final.ppthypertension final.ppt
hypertension final.ppt
derek46236110 visualizações
hypertension final.ppt por raul125935
hypertension final.ppthypertension final.ppt
hypertension final.ppt
raul12593510 visualizações
hypertension final.ppt por ssuser04ffc5
hypertension final.ppthypertension final.ppt
hypertension final.ppt
ssuser04ffc56 visualizações

Mais de jiregnaetichadako

DRUG_CALCULATION_PRESENTATION.pdf por
DRUG_CALCULATION_PRESENTATION.pdfDRUG_CALCULATION_PRESENTATION.pdf
DRUG_CALCULATION_PRESENTATION.pdfjiregnaetichadako
18 visualizações27 slides
anaemia-170224190304 (1).pdf por
anaemia-170224190304 (1).pdfanaemia-170224190304 (1).pdf
anaemia-170224190304 (1).pdfjiregnaetichadako
7 visualizações82 slides
anemia-170709121059.pdf por
anemia-170709121059.pdfanemia-170709121059.pdf
anemia-170709121059.pdfjiregnaetichadako
16 visualizações44 slides
Regression-Logistic-4.pdf por
Regression-Logistic-4.pdfRegression-Logistic-4.pdf
Regression-Logistic-4.pdfjiregnaetichadako
2 visualizações51 slides
DRUG_CALCULATION_PRESENTATION.pdf por
DRUG_CALCULATION_PRESENTATION.pdfDRUG_CALCULATION_PRESENTATION.pdf
DRUG_CALCULATION_PRESENTATION.pdfjiregnaetichadako
25 visualizações27 slides
2.pdf por
2.pdf2.pdf
2.pdfjiregnaetichadako
33 visualizações66 slides

Mais de jiregnaetichadako(20)

DRUG_CALCULATION_PRESENTATION.pdf por jiregnaetichadako
DRUG_CALCULATION_PRESENTATION.pdfDRUG_CALCULATION_PRESENTATION.pdf
DRUG_CALCULATION_PRESENTATION.pdf
jiregnaetichadako18 visualizações
anaemia-170224190304 (1).pdf por jiregnaetichadako
anaemia-170224190304 (1).pdfanaemia-170224190304 (1).pdf
anaemia-170224190304 (1).pdf
jiregnaetichadako7 visualizações
anemia-170709121059.pdf por jiregnaetichadako
anemia-170709121059.pdfanemia-170709121059.pdf
anemia-170709121059.pdf
jiregnaetichadako16 visualizações
Regression-Logistic-4.pdf por jiregnaetichadako
Regression-Logistic-4.pdfRegression-Logistic-4.pdf
Regression-Logistic-4.pdf
jiregnaetichadako2 visualizações
DRUG_CALCULATION_PRESENTATION.pdf por jiregnaetichadako
DRUG_CALCULATION_PRESENTATION.pdfDRUG_CALCULATION_PRESENTATION.pdf
DRUG_CALCULATION_PRESENTATION.pdf
jiregnaetichadako25 visualizações
hypertension-200501101309 (3).pdf por jiregnaetichadako
hypertension-200501101309 (3).pdfhypertension-200501101309 (3).pdf
hypertension-200501101309 (3).pdf
jiregnaetichadako277 visualizações
Hypertension-ppt (1).pptx por jiregnaetichadako
Hypertension-ppt (1).pptxHypertension-ppt (1).pptx
Hypertension-ppt (1).pptx
jiregnaetichadako40 visualizações
coronaryangiogram-140520060959-phpapp01.pdf por jiregnaetichadako
coronaryangiogram-140520060959-phpapp01.pdfcoronaryangiogram-140520060959-phpapp01.pdf
coronaryangiogram-140520060959-phpapp01.pdf
jiregnaetichadako7 visualizações
coronaryangiography-220330142539 (1).pdf por jiregnaetichadako
coronaryangiography-220330142539 (1).pdfcoronaryangiography-220330142539 (1).pdf
coronaryangiography-220330142539 (1).pdf
jiregnaetichadako38 visualizações
coronaryangiographymadhu-151130170912-lva1-app6892 (1).pdf por jiregnaetichadako
coronaryangiographymadhu-151130170912-lva1-app6892 (1).pdfcoronaryangiographymadhu-151130170912-lva1-app6892 (1).pdf
coronaryangiographymadhu-151130170912-lva1-app6892 (1).pdf
jiregnaetichadako12 visualizações
vascularaccessincardiaccatheterization-130517040431-phpapp02 (1).pdf por jiregnaetichadako
vascularaccessincardiaccatheterization-130517040431-phpapp02 (1).pdfvascularaccessincardiaccatheterization-130517040431-phpapp02 (1).pdf
vascularaccessincardiaccatheterization-130517040431-phpapp02 (1).pdf
jiregnaetichadako9 visualizações
NUTRITION 2105-LECTURE 6B.ppt por jiregnaetichadako
NUTRITION 2105-LECTURE 6B.pptNUTRITION 2105-LECTURE 6B.ppt
NUTRITION 2105-LECTURE 6B.ppt
jiregnaetichadako4 visualizações
heartfailurelecture-140122113443-phpapp02 (1).pdf por jiregnaetichadako
heartfailurelecture-140122113443-phpapp02 (1).pdfheartfailurelecture-140122113443-phpapp02 (1).pdf
heartfailurelecture-140122113443-phpapp02 (1).pdf
jiregnaetichadako30 visualizações
lecture_5_drug_acting_on_the_heart (1).ppt por jiregnaetichadako
lecture_5_drug_acting_on_the_heart (1).pptlecture_5_drug_acting_on_the_heart (1).ppt
lecture_5_drug_acting_on_the_heart (1).ppt
jiregnaetichadako6 visualizações
myocardialinfractionramesh-170504133703 (1).pdf por jiregnaetichadako
myocardialinfractionramesh-170504133703 (1).pdfmyocardialinfractionramesh-170504133703 (1).pdf
myocardialinfractionramesh-170504133703 (1).pdf
jiregnaetichadako12 visualizações
myocardialinfarction-150223043527-conversion-gate02 (1).pdf por jiregnaetichadako
myocardialinfarction-150223043527-conversion-gate02 (1).pdfmyocardialinfarction-150223043527-conversion-gate02 (1).pdf
myocardialinfarction-150223043527-conversion-gate02 (1).pdf
jiregnaetichadako11 visualizações
ecg_systemic_approach_12-lead_compressed.pdf por jiregnaetichadako
ecg_systemic_approach_12-lead_compressed.pdfecg_systemic_approach_12-lead_compressed.pdf
ecg_systemic_approach_12-lead_compressed.pdf
jiregnaetichadako32 visualizações
Common_Laboratory_&_Imaging_studies_in_CV_patients_k&_their_interpretation.pptx por jiregnaetichadako
Common_Laboratory_&_Imaging_studies_in_CV_patients_k&_their_interpretation.pptxCommon_Laboratory_&_Imaging_studies_in_CV_patients_k&_their_interpretation.pptx
Common_Laboratory_&_Imaging_studies_in_CV_patients_k&_their_interpretation.pptx
jiregnaetichadako7 visualizações

Último

PATIENTCOUNSELLING in.pptx por
PATIENTCOUNSELLING  in.pptxPATIENTCOUNSELLING  in.pptx
PATIENTCOUNSELLING in.pptxskShashi1
26 visualizações16 slides
Quit Smoking Revolution.pdf por
Quit Smoking Revolution.pdfQuit Smoking Revolution.pdf
Quit Smoking Revolution.pdfGio Ferrandino
18 visualizações56 slides
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad por
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Swetha rani Savala
12 visualizações16 slides
Pulmonary Embolism for Nurses.pptx por
Pulmonary Embolism for Nurses.pptxPulmonary Embolism for Nurses.pptx
Pulmonary Embolism for Nurses.pptxAsraf Hussain
33 visualizações31 slides
eTEP -RS Dr.TVR.pptx por
eTEP -RS Dr.TVR.pptxeTEP -RS Dr.TVR.pptx
eTEP -RS Dr.TVR.pptxVarunraju9
142 visualizações33 slides
corticosteroids.pptx por
corticosteroids.pptxcorticosteroids.pptx
corticosteroids.pptxRAJ K. MAURYA
51 visualizações26 slides

Último(20)

PATIENTCOUNSELLING in.pptx por skShashi1
PATIENTCOUNSELLING  in.pptxPATIENTCOUNSELLING  in.pptx
PATIENTCOUNSELLING in.pptx
skShashi126 visualizações
Quit Smoking Revolution.pdf por Gio Ferrandino
Quit Smoking Revolution.pdfQuit Smoking Revolution.pdf
Quit Smoking Revolution.pdf
Gio Ferrandino18 visualizações
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad por Swetha rani Savala
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Swetha rani Savala12 visualizações
Pulmonary Embolism for Nurses.pptx por Asraf Hussain
Pulmonary Embolism for Nurses.pptxPulmonary Embolism for Nurses.pptx
Pulmonary Embolism for Nurses.pptx
Asraf Hussain33 visualizações
eTEP -RS Dr.TVR.pptx por Varunraju9
eTEP -RS Dr.TVR.pptxeTEP -RS Dr.TVR.pptx
eTEP -RS Dr.TVR.pptx
Varunraju9142 visualizações
corticosteroids.pptx por RAJ K. MAURYA
corticosteroids.pptxcorticosteroids.pptx
corticosteroids.pptx
RAJ K. MAURYA51 visualizações
Peptic ulcer.pdf por UVAS
Peptic ulcer.pdfPeptic ulcer.pdf
Peptic ulcer.pdf
UVAS12 visualizações
Drug induced hepatitis.pptx por ImanShafqat
Drug induced hepatitis.pptxDrug induced hepatitis.pptx
Drug induced hepatitis.pptx
ImanShafqat8 visualizações
Case Study_ AI in the Life Sciences Industry.pptx por Emily Kunka, MS, CCRP
Case Study_ AI in the Life Sciences Industry.pptxCase Study_ AI in the Life Sciences Industry.pptx
Case Study_ AI in the Life Sciences Industry.pptx
Emily Kunka, MS, CCRP34 visualizações
Explore new Frontiers in Medicine with AI.pdf por Anne Marie
Explore new Frontiers in Medicine with AI.pdfExplore new Frontiers in Medicine with AI.pdf
Explore new Frontiers in Medicine with AI.pdf
Anne Marie12 visualizações
Impact of ICF on collaboration and communication por Olaf Kraus de Camargo
Impact of ICF on collaboration and communicationImpact of ICF on collaboration and communication
Impact of ICF on collaboration and communication
Olaf Kraus de Camargo18 visualizações
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f... por PeerVoice
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
PeerVoice6 visualizações
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends por muskansbl01
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness TrendsTop Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
Top Ayurvedic PCD Companies in India Riding the Wave of Wellness Trends
muskansbl0143 visualizações
Epilepsy and Anti epileptic drugs .pdf por A. Gowtham Sashtha
Epilepsy and Anti epileptic drugs .pdfEpilepsy and Anti epileptic drugs .pdf
Epilepsy and Anti epileptic drugs .pdf
A. Gowtham Sashtha9 visualizações
Save 20% on our supplements for kids por novaferrum
Save 20% on our supplements for kidsSave 20% on our supplements for kids
Save 20% on our supplements for kids
novaferrum7 visualizações
Vyadhikshmatva.pptx 1.pptx por Akshay Shetty
Vyadhikshmatva.pptx 1.pptxVyadhikshmatva.pptx 1.pptx
Vyadhikshmatva.pptx 1.pptx
Akshay Shetty32 visualizações
Complications & Solutions in Laparoscopic Hernia Surgery.pptx por Varunraju9
Complications & Solutions in Laparoscopic Hernia Surgery.pptxComplications & Solutions in Laparoscopic Hernia Surgery.pptx
Complications & Solutions in Laparoscopic Hernia Surgery.pptx
Varunraju9129 visualizações

Presentation1 (8).pptx

  • 1. SCHOOL OF NURSING,DEPARTMENT OF CARDIOVASCULAR NURSING SEMINAR PRESENTATION ON HTN BY:JIREGNA ETICHA GSRC /4247/14 : HABTAMU MULU GSRC/4236/14 INSTRUCTOR: (TAKALEGN, MSC IN CVNGP) April 27/2022
  • 4.  Introduction Hypertension Systolic Blood Pressure (SBP) Diastolic Blood Pressure (DBP) > 140 mmHg > 90 mmHg
  • 5. Determinant's BP  BP=CO X SVR=HR X EDV - ESV X SVR  CO=HR X SV  CO=is defined as amount of blood pumped out of each ventricle per minute.  HR=The number of times your heart beats per minute (BPM)  SV=is the volume of blood pumped from one ventricle of the heart with each beat.  SV = EDV – ESV  SRV=Vascular function and structure.
  • 6. INTRODUCTION  Arterial hypertension, simply started is high blood pressure. It is defined as a persistent evaluation of the systolic blood pressure at a level of 140 mm Hg or higher and diastolic blood pressure at a level of 90 mm Hg or higher.
  • 7. CLASSIFICATION OF HTN Classification Systolic blood pressure Diastolic pressure Normal ≤120 ≤ 80 Pre HTN 120-139 80-89 High BP Stage 1 140-159 90-99 High BP Stage 2 Higher than 160 Higher than 100
  • 8. Risk factors  Family history  Age  Gender  Ethnicity  Diabetes  Stress  Obesity  Nutrients  Substance abuse
  • 9. Clinical manifestation  Silent killer  Headache  Nausea and vomiting  Fatigue and confusion  Chest pain  Dizziness  Epistaxis  Angina  Dyspnea  Severe head ache  Blurred vision  Irregular heart beat  papilledema
  • 10. Complications  CAD  LVH  Heart attack / stroke  HF  Retinal damage  Atherosclerosis  Peripheral vascular disease
  • 11. Types 1.Primary HTN / essential 95%  Is the most common form of hypertension.  The cause of primary hypertension is unknown. 2.Secondary HTN 5% 3.Systolic Isolated Hypertension  It’s a high value of systolic pressure, and a normal value of diastolic pressure
  • 12. 4. Hypertensive crisis Hypertensive Urgencies  Hypertensive urgency is acute severe elevation in blood pressure (>180/120 mmHg) without evidence of end organ damage  Usually due to under-controlled HTN. Hypertensive Emergencies  A severe elevation in blood pressure (usually >180/120 mmHg) complicated by impending or progressive target organ dysfunction involving neurological, cardiac or renal systems”  Require lowering of BP within 1 hour to decrease morbidity  Not determined by a BP level, but rather the imminent compromise of vital organ function
  • 13. Risk Factors for Primary Hypertension  Age (> 55 for men; > 65 for women)  Alcohol  Cigarette smoking  Diabetes mellitus  Elevated serum lipids  Excess dietary sodium  Gender Risk Factors for Primary Hypertension  Family history  Obesity (BMI > 30)  Ethnicity (African Americans)  Sedentary lifestyle  Socioeconomic status  Stress
  • 14. 2. Secondary HTN  Some people have high blood pressure caused by an underling condition.  This type of high blood pressure called secondary hypertension. Various condition and medications can lead to secondary hypertension.  Renal artery stenosis  Oral contraceptive pills  Illegal drugs
  • 15. Conti….  Sleep apnea  Drug-induced or drug-related  Chronic kidney disease  Primary aldosteronism  Reno vascular disease  Chronic steroid therapy and Cushing syndrome  Phaeochromocytoma  Acromegaly  Thyroid or parathyroid disease  Coarctation of the aorta
  • 16. Other types of HTN 1. White coat hypertension  White coat syndrome have normal reading at home and only have high readings when their BP is taken by a doctor. 2.Isolated systolic hypertension  It’s not uncommon to have either a systolic number that’s elevate while the diastolic number remains normal.  It’s less common for patients to have elevated diastolic number.  This condition known as isolated systolic hypertension
  • 17. 3.Persistent Hypertension  Characterized by a diastolic blood pressure above 110 to 120 mm Hg.  It results when hypertension is unresponsive to treatment and become a truly severe emergency condition as the pressure continues to rise unchecked
  • 18. Benign hypertension  is a term used to describe uncomplicated hypertension, usually of long duration and mild to moderate severity.  Benign hypertension may be primary or secondary.
  • 19. Malignant hypertension  is a syndrome of markedly elevated BP (diastolic BP over 140 mm Hg) associated with papilledema.  Accelerated hypertension is a syndrome of markedly elevated BP with retinal hemorrhage and exudates.  Accelerated hypertension presumably develops into malignant hypertension if not well managed.
  • 20. Borderline or labile hypertension  is defined as intermittent elevation of blood pressure interspersed with normal readings.  Clients with borderline hypertension still carry an increased risk of developing cardiovascular disease.
  • 21. Resistant hypertension  Resistant hypertension is defined as blood pressure that remains above goal in spite of the concurrent use of 3 antihypertensive agents of different classes. Ideally, one of the 3 agents should be a diuretic and all agents should be prescribed at optimal dose amounts
  • 22. Diagnostic Evaluation  History collection and physical examination  Medical history of diabetes mellitus  Complete blood count  Chest x-ray  ECG  Ophthalmoscopy/Funduscopy
  • 23. laboratory Tests  Renal  Microscopic urinalysis, proteinuria, BUN and/or creatinine  Endocrine,  Serum sodium, potassium, calcium, TSH  Metabolic  Fasting blood glucose, HDL, LDL, and total cholesterol, triglycerides
  • 25. 1.Non pharmacological management  Lifestyle modifications  Sodium restriction  Nutritional therapy  Physical activity  Alcohol restriction  Relaxation technique  Weight reduction  DASH Diet : Dietary Approaches to Stop Hypertension
  • 26. 2.Pharmacological management 1.ACEI  Angiotensin is a hormone in the body that causes blood vessels to narrow.  The angiotensin converting enzyme inhibitors decreases the production of angiotensin and in turn that helps lower blood pressure.  Inhibit ACE and formation of angiotensin II and block its effects  Drugs of choice in co-existent diabetes mellitus, Heart failure  Captopril (25-150 mg/day)  Ramipril (1.25-20 mg/day)  Lisinopril
  • 27. 2. Alpha blockers  These medicines reduces nerve impulses to blood vessels, reducing the effects of natural chemicals that narrow blood vessels.  Block α-1 receptors and cause vasodilation  Reduce peripheral resistance and venous return  Exert beneficial effects on lipids and insulin sensitivity  Drugs of choice in patients with co-existing BPH  Prazocin (2-30 mg/day)  Terazocin (1-20 mg/day)
  • 28. 3. Alpha- beta blockers  In addition to reducing nerve impulses to blood vessels, alpha beta blockers slow the heartbeat to reduce the amount of blood that must be pumped through the vessels.  Help relax your blood vessels, which lowers your blood pressure.  Labetalol (2-30 mg/day)  Carvedilol (12.5-20 mg/day)
  • 29. 4. Angiotensin II receptor blockers  These medications help relax blood vessels by blocking the action, not the formation of a natural chemical that narrows blood vessels.  Block the angiotensin II receptor and inhibit effects of angiotensin II  Drugs of choice in patients with co-existing diabetes mellitus  Valsartan  losartan
  • 30. 5.Beta blockers  These medications reduce the workload on heart and open blood vessels, causing heart to beat slower and with less force.  Example: Atenolol, Metoprolol, nebivolol,  Block β1 receptors on the heart  Block β2 receptors on kidney and inhibit release of renin  Decrease rate and force of contraction and thus reduce cardiac output  Drugs of choice in patients with co-existent coronary heart disease
  • 31. 6. Calcium channel blockers  These medicines will block the movement of extra cellular calcium into the cells and causing vasodilation and decreased heart rate.  These medications relax the muscles of blood vessels. Some slow the heart rate.  Calcium channel blockers relax blood vessels by stopping calcium from entering cells  Cause vasodilation and reduce peripheral resistance  Drugs of choice in elderly hypertensive and those with co-existing asthma  Neutral effect on glucose and lipid levels Example: Amlodipine
  • 32. 7. Diuretics  Example: Hydrochlorothiazide :-Act by decreasing blood volume and cardiac output •  Decrease peripheral resistance during chronic therapy  Drugs of choice in elderly hypertensive  Diuretics help the kidneys get rid of sodium and water from body. This decreases the volume of blood in the body and lowers blood pressure.  Diuretics are also called water pills. They help your kidneys remove some salt (sodium) from your body. As a result, your blood vessels don't have to hold as much fluid and your blood pressure goes down  E.g. chlorothiazide, furosemide  Furosemide (40-240mg/day)  Spironolactone (25-100 mg/day
  • 33. 8.Vasodilators  These medications acting directly on the muscles in the wall of arteries and preventing the muscles from tightening and arteries from narrowing. These medications work directly on the muscles in the walls of arteries.  signal the muscles in the walls of blood vessels to relax E.g. Nitroglycerin, Sodium nitro prusside  Minoxidil (5-100 mg/day)  Hydralazine (50-300 mg/day) 9.Centrally acting drugs  signal your brain and nervous system to relax your blood vessels
  • 34.  Step to Management Lifestyle modifications weight loss, diet, exercise, stop smoking, limit alcohol Medication Diuretics or Beta-Blocker Add second drug or substitute another drug Add third drug and/or substitute second drug Continue adding agents from other classes Referral to hypertensive specialist Step 1 Step 2 Step 3 Step 4 Step 5
  • 35. Algorithm of HTN Management